PDCD1 and acute myeloid leukemia: In this study, we demonstrated that BET bromodomain inhibition suppressed PD-1 and Tim-3 expression via BRD4 and NFAT2, and augmented the cytokine production of T cells from AML patients, as well as rescued exhausted T cells via reducing the expression of PD-1 and Tim-3.